Share this video  

NACLC 2022 | Considerations for duration and de-escalation of immunotherapy in lung cancer

Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, comments on the appropriate duration of immunotherapy for patients with lung cancer. The current standard of two years is derived from clinical trials and there is growing evidence that a shorter duration of therapy may benefit some patients. However patients with more unstable disease will have better outcomes with longer regimens as demonstrated in the CheckMate 153 trial (NCT00730639), where progression-free survival and overall survival was superior by continuing treatment beyond one year. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Ryan Gentzler, MD, discloses the following commercial interests:

Consultant/Advisory Board: AstraZeneca, Daiichi Sankyo, Sanofi, OncoCyte, Blueprint Medicines, Jazz Pharmaceuticals, Mirati, Pfizer, Gilead

Honorarium: Targeted Oncology, SITC, Rockpointe CME, OncLive, Clinical Care Options

Contracted Support/Research Grant (Institution): Pfizer, Takeda, Jounce Therapeutics, Janssen, BMS, Merck, Daiichi Sankyo, Helsinn, Mirati, RTI International, AstraZeneca, Chugai, Amgen

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter